Isotechnika Pharma Inc IPHAF

RE: RE: 0.30

[redrill]

"for sure we're not going to see approval"

Many will disagree with that statement................Could the outstanding issues possibly be 1)pricing for multiple applications if other than Lux is marketing this drug?  2)  control of off label usage as this drug definitely seems to have several viable uses other than opthamalogy. 3) data submitted from both transplant and psoarasis trials, issue as to when application for the use in these areas is to be submitted.......The speculation is quite entertaining on this board!!!!!